Recipients › North Carolina › Glaxosmithkline, LLC
Recipient organisation · UEI FRHTPHMZMX47
Glaxosmithkline, LLC
- Corporation
- Foreign-owned
USAspending caveat. Figures are obligations reported by federal agencies to USAspending.gov, not payments. In USAspending's words: "An outlay occurs when federal money is actually paid out, not just promised to be paid ('obligated')." "Every agency has a Senior Accountable Official who must officially certify that the quarterly financial data submitted by their agency is accurate and complete." "If there are any discrepancies in procurement data, FPDS is the authoritative source." Contract data for the Department of Defense and the U.S. Army Corps of Engineers is published with a 90-day delay. Data loaded 30 Sep 2026. View the USAspending recipient profile.
Glaxosmithkline, LLC, of Durham, NC, was obligated $4.0B in federal awards across the 4 fiscal years in which it reached the $1.0M listing floor (2023, 2024, 2025, 2026).
In FY2026, the most recent complete fiscal year, obligations were $1.0B, of which $22M (2%) came through contracts.
That is about level on FY2025 ($980M).
Glaxosmithkline, LLC ranks 5 of 633 listed organisations located in NC by five-year obligations, and 256 of 30,000 nationally.
Its $1.0M-plus awards since FY2023 came from Department of Health and Human Services and Department of Defense: 15 awards worth $128M in total award value.
Its largest contract industry is NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)), where it ranks 17 of 180 organisations by the value of $1.0M-plus awards.
USAspending lists its parent organisation as Glaxosmithkline PLC.
Obligations by fiscal year contracts vs assistance
| Fiscal year | All obligations | Contracts | Assistance | Change |
|---|---|---|---|---|
| FY2023 | $843,381,565 | $12,813,146 | $830,568,419 | — |
| FY2024 | $1,165,095,366 | $62,728,478 | $1,102,366,888 | +38% |
| FY2025 | $980,458,670 | $29,908,789 | $950,549,881 | -16% |
| FY2026 | $1,042,469,598 | $21,521,795 | $1,020,947,803 | +6% |
| FY2027 to date | under $1.0M | — | — | — |
A fiscal year runs 1 October to 30 September. "Contracts" are procurement award types A–D; "assistance" is everything else (grants, direct payments, loan subsidy cost, insurance, other). The contracts column is listed only where contract obligations alone reached $1.0M; the assistance figure is the remainder and may therefore include up to $1.0M of contracts.
Compared with its state and the largest recipients five listed years
| Measure | This organisation | Largest in NC | Largest nationally |
|---|---|---|---|
| Five-year obligations (listed years) | $4.0B | $114B | $416B |
| FY2026 obligations | $1.0B | $33B | $118B |
| Contracts, five years | $127M | $4.9M | $94B |
| Assistance, five years | $3.9B | $114B | $416B |
| Rank by five-year obligations | 256 of 30,000 | 1 of 633 in NC | 1 |
Largest in state: North Carolina Department of Health & Human Services. Largest nationally: Health Care Services, California Department of. Rankings count organisations located in the state, by the sum of their listed fiscal years.
Awarding agencies $1.0M+ awards since FY2023
| # | Agency | Awards | Award value | Share |
|---|---|---|---|---|
| 1 | Department of Health and Human Services | 13 | $125M | 98% |
| 2 | Department of Defense | 2 | $2.9M | 2% |
Contract industries NAICS
Rank within NAICS 541714: 17 of 180 organisations by $1.0M+ award value; see Research and Development in Biotechnology (except Nanobiotechnology).
Places of performance $1.0M+ awards
Counties: Durham County, NC $112M · Fulton County, GA $8.7M · Lancaster County, PA $4.7M · Oklahoma County, OK $2.8M
Largest awards begun since FY2023
| Awarding agency | Type | Industry or program | Award value | Begun | Place | Record |
|---|---|---|---|---|---|---|
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDefinitive Contract | 325412 Pharmaceutical Preparation Manufacturing | $27M | 26 Sep 2025 | NC | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $18M | 10 May 2024 | NC | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $15M | 27 Feb 2024 | NC | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $14M | 20 Feb 2024 | NC | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $12M | 17 Jun 2024 | NC | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $8.8M | 13 Jun 2025 | NC | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 325412 Pharmaceutical Preparation Manufacturing | $8.7M | 16 Aug 2023 | GA | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $7.8M | 20 Feb 2024 | NC | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $4.7M | 12 Dec 2022 | PA | USAspending |
| Department of Health and Human ServicesIndian Health Service | ContractDelivery Order | 325412 Pharmaceutical Preparation Manufacturing | $2.8M | 20 Jun 2024 | OK | USAspending |
| Department of Health and Human ServicesCenters for Disease Control and Prevention | ContractDelivery Order | 325411 Medicinal and Botanical Manufacturing | $2.1M | 10 Aug 2023 | NC | USAspending |
| Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response | ContractDelivery Order | 541714 Research and Development in Biotechnology (except Nanobiotechnology) | $2.0M | 17 Feb 2023 | NC | USAspending |
Award value is the amount obligated to the award to date as USAspending reports it. Descriptions below are USAspending's text, unedited and truncated; those that appear to name a person are withheld.
- $27M, Department of Health and Human Services, 26 Sep 2025: RELENZA (ZANAMIVIR) ROTADISK, 5MG
- $18M, Department of Health and Human Services, 10 May 2024: THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL COUNTERMEASURES (MCMS) FOR PANDEMIC INFLUENZA AND EMERGING DISEASES PR
- $15M, Department of Health and Human Services, 27 Feb 2024: THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) TO SUPPORT THE COVID-19 FEDERAL RESPONSE- MULTI-DOSE VIALS FOR HHS UND
- $14M, Department of Health and Human Services, 20 Feb 2024: THE PURPOSE OF THIS HHS TASK ORDER IS TO PROCURE SERVICES FOR THE STORAGE AND STABILITY OF BULK LOTS & FINAL CONTAINERS OF-ADJUVANT( AS03) COVID-19 FUNDS.
- $12M, Department of Health and Human Services, 17 Jun 2024: THIS TASK ORDER ESTABLISHES SERVICES FOR STORAGE AND STABILITY OF AS03 ADJUVANT MANUFACTURED TO SUPPORT THE COVID-19 FEDERAL RESPONSE IN BULK LOTS AND FINAL CON
- $8.8M, Department of Health and Human Services, 13 Jun 2025: CLIN 1005, CGMP ADJUVANT: CLINICAL OR COMMERCIAL SCALE BULK LOT(S)
- $8.7M, Department of Health and Human Services, 16 Aug 2023: RELENZA (ZANAMIVIR) ROTADISK, SMG, NDC 00173-0681-22
- $7.8M, Department of Health and Human Services, 20 Feb 2024: THE PURPOSE OF THIS TASK ORDER IS TO PROCURE STORAGE AND STABILITY FOR ANTIGENS AND ADJUVANTS FROM PRIOR CONTRACTS FOR THE DEPARTMENT OF HEALTH AND HUMAN SERVIC
Questions and answers
How much federal money does Glaxosmithkline, LLC receive?
$4.0B in award obligations over the fiscal years it is listed for (FY2023: $843M; FY2024: $1.2B; FY2025: $980M; FY2026: $1.0B). Years not listed were under the $1.0M floor. Obligations are binding commitments, not payments made.
Which agencies award to Glaxosmithkline, LLC?
By the value of $1.0M-plus awards begun since FY2023: Department of Health and Human Services ($125M) and Department of Defense ($2.9M).
What is the money for?
Contracts are classified under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology), NAICS 325412 Pharmaceutical Preparation Manufacturing and NAICS 325411 Medicinal and Botanical Manufacturing.
Where is the work performed?
Primary places of performance for its larger awards: NC ($112M), GA ($8.7M), PA ($4.7M) and OK ($2.8M).
Is Glaxosmithkline, LLC a large federal recipient?
It ranks 256 of 30,000 organisations on this site by five-year obligations and 5 of 633 located in NC. The site covers organisations with at least $1.0M in a fiscal year; individuals are excluded.
Where does this data come from?
USAspending.gov (U.S. Treasury), award transactions as loaded on 30 Sep 2026; fiscal-year totals via the spending-by-category endpoint and award lists via the award search endpoint. The USAspending recipient profile is the authoritative record.
Provenance
Source: USAspending.gov API v2 (U.S. Department of the Treasury, Bureau of the Fiscal Service), CC0. Fiscal-year obligations from the spending-by-category recipient ranking by recipient state (listing floor $1.0M per year); awards from the award search endpoint (new awards of $1.0M or more by base obligation date); parent and business categories from the recipient profile where fetched. Closed fiscal years are snapshots taken after year end; FY2027 is refreshed on each build. Data loaded by USAspending on 30 Sep 2026. Individuals and sole proprietors are excluded at ingest. Errors in processing are corrected at the next build; see corrections and the methodology.